Filing Details
- Accession Number:
- 0000899243-21-041580
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-26 17:30:00
- Reporting Period:
- 2021-10-26
- Accepted Time:
- 2021-10-26 17:30:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1840233 | Xilio Therapeutics Inc. | XLO | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1725443 | Rivervest Venture Fund Iv, L.p. | 101 S. Hanley Road, Suite 1850 St. Louis MO 63105 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-10-26 | 832,120 | $0.00 | 832,120 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-10-26 | 359,324 | $0.00 | 1,191,444 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-10-26 | 250,000 | $16.00 | 1,441,444 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2021-10-26 | 832,120 | $0.00 | 832,120 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2021-10-26 | 359,324 | $0.00 | 359,324 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 26, 2021. The shares have no expiration date.
- The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest IV") are indirectly held by RiverVest Venture Partners IV, L.P. ("RiverVest Partners IV"), which is the general partner of RiverVest IV. RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV.
- The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and Niall O'Donnell. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers share voting and dispositive power with regard to the securities directly held by RiverVest Venture Fund IV, L.P.
- RiverVest IV purchased the shares in the Issuer's initial public offering.
Billionaire Hedge Funds
